

83804\_Auto\_Edited.docx

**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 83804

**Manuscript Type:** ORIGINAL ARTICLE

*Retrospective Study*

**Association of vitamin D and polymorphisms of its receptor with antiviral therapy in pregnant women with hepatitis B**

Wang R *et al.* VD in preventing MTCT of HBV

Rui Wang, Xia Zhu, Xuan Zhang, Huan Liu, Yu-Lin Ji, Yong-Hua Chen

## Abstract

### BACKGROUND

The interruption of mother-to-child transmission (MTCT) is considered important to decrease the individual and population morbidity of hepatitis B virus (HBV) infection as well as the global burden of hepatitis B. Serum vitamin D (VD) is associated with hepatitis B.

### AIM

To assess whether baseline VD levels and single nucleotide polymorphisms of the VD receptor gene (VDR SNPs) are associated with the efficacy of tenofovir disoproxil fumarate (TDF) in the prevention of MTCT in pregnant women with high HBV viral loads.

### METHODS

Thirty-eight pregnant women who were at high risk for MTCT of HBV (those with an HBV DNA level  $\geq 2 \times 10^5$  IU/mL during 12-24 wk of gestation) receiving antiviral therapy of TDF between June 1, 2019 and June 30, 2021 in Mianyang were included in this retrospective study. The women received 300 mg TDF once daily from gestational weeks 24-28 until 3 mo after delivery. To further characterize the clinical relevance of maternal serum HBV DNA levels, we stratified patients according to HBV DNA level as follows: Those with levels  $< 2 \times 10^5$  (full responder group) *vs* those levels  $\geq 2 \times 10^5$  IU/mL (partial responder group) at delivery. Serum levels of 25-hydroxyvitamin D [25(OH)D], liver function markers, virological parameters, VDR SNPs and other clinical parameters were collected to analyze their association with the efficacy of TDF. The Mann-Whitney *U* test or *t* test was used to analyze the serum levels of 25(OH)D in different groups. Multiple linear regressions were utilized to analyze the determinants of the maternal HBV DNA level at delivery. Univariate and multivariate logistic regression analyses were employed to explore the association of targeted antiviral effects with various characteristics at baseline and delivery.

## RESULTS

A total of 38 pregnant women in Mianyang City at high risk for MTCT of HBV were enrolled in the study. The MTCT rate was 0%. No mother achieved hepatitis B e antigen or hepatitis B surface antigen (HBsAg) clearance at delivery. Twenty-three (60.5%) participants were full responders, and 15 (39.5%) participants were partial responders according to antiviral efficacy. The present study showed that a high percentage (76.3%) of pregnant women with high HBV viral loads had deficient ( $< 20$  ng/mL) or insufficient ( $\geq 20$  but  $< 31$  ng/mL) VD levels. Serum 25(OH)D levels in partial responders appeared to be significantly lower than those in full responders both at baseline ( $25.44 \pm 9.42$  vs  $17.66 \pm 5.34$  ng/mL,  $P = 0.006$ ) and delivery ( $26.76 \pm 8.59$  vs  $21.24 \pm 6.88$  ng/mL,  $P = 0.044$ ). Serum 25(OH)D levels were negatively correlated with maternal HBV DNA levels [ $\log(10)$  IU/mL] at delivery after TDF therapy ( $r = -0.345$ ,  $P = 0.034$ ). In a multiple linear regression analysis, maternal HBV DNA levels were associated with baseline maternal serum 25(OH)D levels ( $P < 0.0001$ ,  $\beta = -0.446$ ), BMI ( $P = 0.03$ ,  $\beta = -0.245$ ), baseline maternal  $\log_{10}$  HBsAg levels ( $P = 0.05$ ,  $\beta = 0.285$ ) and cholesterol levels at delivery ( $P = 0.015$ ,  $\beta = 0.341$ ). Multivariate logistic regression analysis showed that baseline serum 25(OH)D levels (OR = 1.23, 95%CI: 1.04-1.44), maternal VDR Cdx2 TT (OR = 0.09, 95%CI: 0.01-0.88) and cholesterol levels at delivery (OR = 0.39, 95%CI: 0.17-0.87) were associated with targeted antiviral effects (maternal HBV DNA levels  $< 2 \times 10^5$  at delivery).

## CONCLUSION

Maternal VD levels and VDR SNPs may be associated with the efficacy of antiviral therapy in pregnant women with high HBV viral loads. Future studies to evaluate the therapeutic value of VD and its analogs in reducing the MTCT of HBV may be justified.

**Key Words:** Hepatitis B virus; Vitamin D; Vitamin D receptor polymorphism; Antiviral therapy; Pregnancy; Mother-to-child transmission

Wang R, Zhu X, Zhang X, Liu H, Ji YL, Chen YH. Association of vitamin D and polymorphisms of its receptor with antiviral therapy in pregnant women with hepatitis B. *World J Gastroenterol* 2023; In press

**Core Tip:** This retrospective study investigated the influence of vitamin D (VD) levels and single nucleotide polymorphisms of the VD receptor gene (VDR SNPs) on the efficacy of tenofovir disoproxil fumarate in preventing mother-to-child transmission in 38 pregnant women with high hepatitis B viral loads. We demonstrate a significant association between low serum levels of 25-hydroxyvitamin D and high levels of hepatitis B virus replication in pregnant women with high hepatitis B viral loads, and maternal VD levels as well as VDR SNPs may be associated with the efficacy of antiviral therapy.

## <sup>20</sup> INTRODUCTION

Hepatitis B virus (HBV) infection is a serious public health problem that causes a very large medical and economic burden worldwide. <sup>14</sup> Mother-to-child transmission (MTCT) is the main route of HBV transmission, accounting for 30%-50% of chronic infections in China<sup>[1]</sup>. In particular, China is a major contributor to achieving the global goal of eliminating hepatitis B as a threat to public health by 2030<sup>[2]</sup>. The interruption of MTCT is considered <sup>12</sup> important to decrease the individual and population morbidity of HBV infection as well as the global burden of hepatitis B. In recent years, Chinese scholars have continuously published and updated the management algorithm for the prevention of the MTCT of HBV, which has achieved good clinical application<sup>[3,4]</sup>. To date, the use of antiviral drugs in combination with immunoprophylaxis in pregnant women has been shown to be safe and effective in reducing the MTCT of HBV<sup>[4]</sup>.

<sup>23</sup> Vitamin D (VD) is a fat-soluble steroid hormone that is widely found in systemic organs and tissues, including the brain, bones, cardiac system and immune system, and has multiple effects on human health and <sup>8</sup> many diseases, including infectious diseases. In fact, VD deficiency has been detected in a variety of chronic liver diseases, including

chronic viral hepatitis<sup>[5-8]</sup>. Moreover, VD deficiency is common among patients with chronic hepatitis B infection and is associated with adverse clinical outcomes<sup>[9]</sup>. Similarly, VD levels are lower in pregnant women with chronic HBV infection than in healthy pregnant women<sup>[10]</sup>. Clinical and epidemiological studies support the role of VD in inhibiting HBV infection, and this antiviral effect is widely attributed to the VD receptor (VDR)<sup>[11]</sup>.

Different studies have focused on single nucleotide polymorphisms of the VDR gene (VDR SNPs) and HBV. VDR ApaI has been associated with the presence of hepatitis B surface antigen (HBsAg) and viral loads at different times<sup>[12]</sup>. In addition to its effect on viruses, VD plays an important role for the mother and fetus during pregnancy and has been associated with influencing adverse perinatal events.

However, few data are available with regard to the association of VD levels and VDR SNPs with clinical parameters and treatment outcomes in pregnant women with high HBV viral loads. The aims of our present retrospective study were to study whether baseline VD levels and VDR SNPs were associated with the efficacy of tenofovir disoproxil fumarate (TDF) in the prevention of MTCT in pregnant women with high HBV viral loads.

## **MATERIALS AND METHODS**

### ***Study population***

This was a retrospective study. As part of “The National Science & Technology Pillar Program during the 13<sup>th</sup> Five-year Plan Period”, HBsAg-positive pregnant women receiving TDF were included from Mianyang between June 1, 2019 and June 30, 2021. The present study was approved by the Institutional Review Board of the West China Hospital, Sichuan University (No. 2019-151), and informed consent was obtained from all patients before recruitment.

Pregnant women screened for HBV DNA at high risk for MTCT (HBV DNA thresholds  $\geq 2 \times 10^5$  IU/mL) according to WHO recommendations during 12-24 wk of gestation and completed antiviral therapy as required were included in the study. Women received 300

mg TDF once daily from gestational weeks 24-28 until 3 mo after delivery, in addition to HBV immune globulin and three doses of HBV vaccination, including a birth dose given to the neonate. The main exclusion criteria were as follows: (1) Coinfection of syphilis, *Toxoplasma gondii*, human immunodeficiency viruses, or types of viral hepatitis other than HBV; (2) major systemic disease, including heart disease, malignant neoplasm, or renal insufficiency; (3) evidence of liver cirrhosis, hepatic decompensation and other liver diseases such as drug-induced hepatitis, autoimmune liver disease, or alcoholic liver disease; (4) evidence of congenital anomalies of the fetus; (5) antiviral treatment within a short period of time prior to treatment with TDF or failure to complete TDF antiviral therapy as required; and (6) incomplete data, including basic information, VD levels before and after treatment, VDR SNPs, virological indicators, *etc.*

#### ***Data collection and definition***

The basic information of the pregnant woman including age, height, weight, season of blood sample collection and other basic information was collected. Meanwhile, maternal virological indicators, including HBsAg, hepatitis B e antigen (HBeAg) and HBV DNA, were recorded before antiviral treatment and at delivery after antiviral treatment. Moreover, common clinical parameters before antiviral treatment and at delivery after antiviral treatment including peripheral blood count, liver function, kidney function and other parameters were also collected. Laboratory tests were performed according to our previous description<sup>[13,14]</sup>.

Previously collected blood samples were used to assess maternal VD levels and VDR SNPs. In particular, VD was assessed at baseline and at the time of delivery by measuring serum 25-hydroxyvitamin D [25(OH)D] levels. Serum 25(OH)D was analyzed by LCMS/MS (Agilent Technologies Inc., LCMS/MS1260-6470, CA, United States) after hexane extraction with deuterated 25(OH)D as a control as previously described<sup>[15]</sup>. Levels of VD were categorized as follows: < 20 ng/mL = deficient; ≥ 20 but < 31 ng/mL = insufficient; and ≥ 31 ng/mL = normal. Genomic DNA was isolated from blood samples (MagNA Pure Compact, Roche). VDR SNPs were assessed through a real-time PCR allelic



discrimination system (LightCycler 96, Roche). We investigated the following gene SNPs: VDR: rs7975232 (ApaI)C>A, rs11568820 (Cdx2)T>C, rs2228570 (FokI)A>G, rs1544410 (BsmI)C>T, rs731236 (TaqI)A>G.

The primary outcomes were the changes in the maternal viral load (HBV DNA level) at baseline and the time of delivery. A sustained virological response was defined as an HBV DNA level lower than  $2 \times 10^5$  IU/mL at delivery. We aimed to determine whether the levels of VD and VD SNPs were associated with the antiviral effects of TDF in interrupting MTCT during the peripartum period.

### Statistical analysis

All statistical analyses were carried out using SPSS Version 26. Categorical variables are represented as frequencies and percentages, and continuous variables are represented as medians (interquartile ranges) or means  $\pm$  SD. The outcomes were compared between the two groups using  $\chi^2$  tests or Fisher's exact test for categorical variables and the Wilcoxon signed-rank test or Student's  $t$  test for continuous variables. Associations between VD and each of the baseline demographic and lab values were assessed in univariate analyses using general linear models. Univariate and multivariate logistic regression analyses were employed to explore the association of targeted antiviral effects (HBV DNA levels  $< 2 \times 10^5$  at delivery) with various characteristics at baseline and delivery. Factors with a  $P$  value  $< 0.1$  in univariate analysis were considered in multivariate analysis. The statistical test was 2-sided, and a  $P$  value  $< 0.05$  was considered statistically significant.

## RESULTS

### Patient characteristics

The baseline characteristics, laboratory data, and VDR SNPs of the patients are presented in Table 1. No mother achieved HBeAg or HBsAg clearance at delivery. The decrease in HBV DNA levels from baseline to delivery was significant ( $P < 0.001$ ). A total of 100% of the infants had negative HBsAg and undetectable HBV DNA levels at delivery; thus, the MTCT rate was 0%. To further characterize the clinical relevance of maternal serum HBV



DNA levels, we stratified patients according to serum HBV DNA levels as follows: those with levels  $< 2 \times 10^5$  (full responder group) *vs* those with levels  $\geq 2 \times 10^5$  IU/mL (partial responder group) at delivery. Mothers with serum HBV DNA viral loads below this threshold are generally considered low risk for MTCT. Twenty-three (60.5%) participants were full responders, and 15 (39.5%) participants were partial responders according to antiviral efficacy. Full and partial responders were similar in age (29.09 *vs* 28.73 years) and body mass index (BMI) (23.15 *vs* 21.42 kg/m<sup>2</sup>).

In the virological indicators related to HBV, there was no significant difference in the HBsAg log<sub>10</sub> and HBeAg log<sub>10</sub> values between the two groups both at baseline and delivery. The serum HBV DNA concentration was not significantly different between the two groups at baseline, but the serum HBV DNA concentration of full responders was significantly lower than that of partial responders at delivery after antiviral treatment [log<sub>10</sub>, 3.61 (2.88, 4.46) *vs* 7.41 (5.79, 7.9),  $P < 0.0001$ ].

For the laboratory test results, there were no significant differences between full and partial responders in most of the main laboratory indices before and after antiviral therapy, including hemoglobin, white blood cell count, platelets, neutrophils, lymphocytes, total bilirubin, albumin, alanine aminotransferase, triglycerides, creatinine, alkaline phosphatase, and gamma-glutamyl transferase. However, cholesterol levels were lower in complete responders than in partial responders at delivery after treatment ( $4.87 \pm 0.79$  *vs*  $5.56 \pm 0.96$  mg/dL,  $P = 0.001$ ), but there was no significant difference at baseline.

### Serum 25(OH)D levels

There was no VD or multivitamin supplementation between baseline and delivery. The mean baseline serum 25(OH)D level of the entire cohort was similar to the serum 25(OH)D level at delivery, with no significant difference ( $22.37 \pm 8.85$  *vs*  $24.58 \pm 8.32$  ng/mL,  $P = 0.139$ ). Of the 38 patients in the entire cohort, 18 (47.4%), 11 (28.9%), and 9 (23.7%) had severe VD deficiency, VD insufficiency or normal serum VD levels, respectively.

In the absence of significant seasonal differences for the collected blood samples, VD deficiency and insufficiency were highly prevalent in partial responders (73.3%, 20% vs 30.4%, 34.8%,  $P = 0.021$ ). Overall, the serum 25-hydroxyvitamin D3 [25(OH)D3] level in partial responders appeared to be significantly lower than that in full responders both at baseline ( $25.44 \pm 9.42$  vs  $17.66 \pm 5.34$  ng/mL,  $P = 0.006$ ) and delivery ( $26.76 \pm 8.59$  vs  $21.24 \pm 6.88$  ng/mL,  $P = 0.044$ ). In addition, the VDR SNP assay showed no significant difference between full and partial responders based on VDR SNPs, including VDR Cdx2, Bsm1, FokI, Taq1 and Apa1.

#### *Relationship between baseline serum 25(OH)D levels and virological parameters*

Maternal HBsAg serum levels were not associated with serum 25(OH)D levels (data not shown). Interestingly, maternal Log10 HBV DNA levels at delivery and baseline serum 25(OH)D levels showed a significant, inverse correlation ( $P = 0.034$ , Figure 1). Therefore, we performed multiple linear regression analysis of the determinants of maternal HBV DNA levels at delivery. In both univariate and multivariate analyses, baseline maternal serum 25(OH)D levels were the strongest determinant of low maternal HBV DNA levels ( $P = 0.034$  and  $< 0.0001$ , respectively; Table 2), together with BMI, baseline maternal log10 HBsAg levels and cholesterol levels at delivery.

We further performed univariate and multivariate regression analyses to characterize the relationship between the serum level of 25(OH)D and targeted antiviral effects. The baseline serum 25(OH)D level was independently associated with targeted antiviral effects (maternal HBV DNA levels  $< 2 \times 10^5$  at delivery) in a multivariate regression model [OR 1.23 (1.04-1.44),  $P = 0.026$ ], together with maternal VDR Cdx2 TT and cholesterol levels at delivery (Table 3).

## **DISCUSSION**

The present study showed that a high percentage (76.3%) of pregnant women with high HBV viral loads had deficient ( $< 20$  ng/mL) or insufficient ( $\geq 20$  but  $< 31$  ng/mL) VD levels. There was a profound association between low serum 25(OH)D levels and higher

levels of maternal HBV replication at delivery after TDF therapy. In a multiple linear regression analysis, maternal HBV DNA levels were associated with baseline maternal serum 25(OH)D levels, BMI, baseline maternal log<sub>10</sub> HBsAg levels and cholesterol levels at delivery. Finally, we observed that baseline serum 25(OH)D levels, maternal VDR Cdx2 TT and cholesterol levels at delivery were associated with targeted antiviral effects (maternal HBV DNA levels  $< 2 \times 10^5$  at delivery) in a multivariate regression model.

In the human body, VD and its receptors are widely involved in a variety of life processes, regulating the nervous, immune and endocrine systems through related signaling pathways. Many studies have been conducted to reveal the association effect of VD and its receptors on HBV infection and its development. VD deficiency or declines can be detected in a variety of chronic liver diseases<sup>[5,7,16]</sup> and is associated with adverse clinical outcomes<sup>[9,16]</sup>. Abnormally low VD levels are highly prevalent among untreated patients with active chronic hepatitis B infection<sup>[6]</sup>.

For a special group of people, such as pregnant females, VD is a vital nutrient that is important for both the mother and fetus in the perinatal period, and prenatal VD supplementation may reduce the risk of many adverse events and yield potential benefits. A previous study showed that pregnant women with HBV in China had lower VD levels than healthy pregnant women<sup>[10]</sup>. Our present study also showed that a high percentage (76.3%) of pregnant women with high HBV viral loads had deficient (18/38) or insufficient (11/38) VD levels, while only approximately 25.00% (9/38) had adequate VD levels. Our results suggested that abnormally low VD levels may be a common phenomenon in untreated pregnant women with high HBV viral loads in China.

Based on the evidence provided by a companion systematic review that addressed HBV DNA thresholds for identifying pregnant women at risk of MTCT, the WHO recommends administering TDF to pregnant women infected with HBV with high viral loads ( $\geq$  HBV DNA thresholds  $\geq 2 \times 10^5$  IU/mL) from week 28 of pregnancy until at least childbirth to prevent MTCT, in addition to three doses of hepatitis B vaccination, including a birth dose given to the neonate. A recent meta-analysis showed that peripartum antiviral prophylaxis is highly effective at reducing the risk of the MTCT of

HBV<sup>[17]</sup>, which supports the 2020 WHO recommendation of administering antivirals during pregnancy, specifically TDF, for the prevention of the MTCT of HBV.

There is growing evidence that VD is associated with infectious diseases and immunity against infection and that VD supplementation has therapeutic potential in the treatment of infectious diseases<sup>[18,19]</sup>. Low maternal VD levels (< 32 ng/mL) were associated with a higher risk of the MTCT of HIV, and children born to women with low VD levels had a higher risk of death during follow-up<sup>[20]</sup>. Clinical and epidemiological studies support the role of VD in inhibiting HBV infection, and this antiviral effect is widely attributed to the VDR<sup>[11]</sup>. Hepatic VDR protein expression was significantly lower in patients with chronic HBV infection, and hepatic VDR expression was inversely correlated with hepatic inflammation and fibrosis<sup>[21]</sup>, which could partly explain the more pronounced decrease in viral DNA in patients with higher VD levels after receiving antiviral therapy in our study.

The present study revealed a profound association between low serum 25(OH)D levels and higher levels of maternal HBV replication at delivery after TDF therapy. Consistent with our previous study, serum 25(OH)D levels were highly negatively correlated with HBV DNA levels<sup>[14]</sup>. Therefore, for HBV-infected patients, especially pregnant women, monitoring of VD levels is advocated, and increasing VD levels to a normal range in appropriate ways may be beneficial in maintaining low levels of HBV DNA. It is expected that more in-depth studies will be performed to elucidate the mechanism of the effect of VD on HBV infection and its development, treatment and prognosis, which may offer attractive therapeutic opportunities for the treatment of chronic hepatitis B infection.

A number of studies have recently focused on the association between VDR SNPs and the disease characteristics of HBV infection. Some genotypes in VDR FokI increased the risk of HBV infection in a meta-analysis<sup>[22]</sup>. In addition, the VDR ApaI SNP was associated with viral load and the presence of HBsAg at different times, and pharmacogenetic data could help physicians identify HBV patients with a higher probability of achieving a good response<sup>[12]</sup>. In addition, VDR SNPs are correlated with HBV viral load and the severity of liver disease<sup>[23]</sup> and may be associated with occult hepatitis B infection<sup>[9]</sup>. Our results



revealed that VDR Cdx2 TT was a hindering factor in achieving targeted antiviral therapeutic effects (HBV DNA levels  $< 2 \times 10^5$  at delivery) after TDF therapy. In pregnant women, increasing VD levels to within the normal range may help to achieve targeted antiviral treatment effects, especially in those with VDR Cdx2 TT. More basic and clinical studies are warranted for VD supplementation combined with antiviral therapy and immunoprophylaxis to block MTCT.

VD and cholesterol metabolism overlap significantly in the pathways that promote their biosynthesis and have a complex bidirectional relationship<sup>[24]</sup>. In our study, there was no significant difference in cholesterol levels between the full and partial responders before antiviral therapy, but cholesterol levels were lower in full responders after treatment. Similarly, in another study, for treatment-naïve patients with chronic hepatitis B infection, total cholesterol levels showed a decreasing trend during 42 mo of TDF treatment<sup>[25]</sup>. Moreover, higher total cholesterol concentrations were associated with lower 25(OH)D concentrations<sup>[26]</sup>, and VD supplementation appeared to have a beneficial effect on reducing total serum cholesterol levels<sup>[27]</sup>. In addition, VDR SNPs were associated with dyslipidemia in Chinese populations, and some variants may increase susceptibility to dyslipidemia<sup>[28]</sup>. Together, the difference in cholesterol levels after antiviral therapy may be due to differences in VD levels, VDR SNPs, and reactions to antiviral therapy.

Some limitations of the present study should be acknowledged. Most importantly, due to the type of study, the clinical correlations cannot be interpreted as causal relationships. Therefore, a suggestive functional link between VD metabolism and HBV replication remains elusive. Furthermore, the sample size included in this study was limited. Third, there are still some possible confounding factors that have not been considered. Although factors such as the season of blood collection were taken into account, other factors such as dietary habits, the duration of sunlight exposure and the ultraviolet intensity of pregnant women's living environments may also affect maternal VD levels.

## **CONCLUSION**

In summary, we demonstrate<sup>11</sup> a significant association between low serum levels of 25(OH)D and high levels<sup>27</sup> of HBV replication in pregnant women with high HBV viral loads, and maternal VD levels as well as VDR SNPs may be associated with the efficacy of antiviral therapy. Future studies to evaluate the therapeutic value of VD and its analogs in reducing the MTCT of HBV may be justified.

16%

SIMILARITY INDEX

---

PRIMARY SOURCES

---

- 1

Anna L Funk, Ying Lu, Kyoko Yoshida, Tianshuo Zhao et al. "Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis", The Lancet Infectious Diseases, 2020

Crossref

76 words — 2%

---
- 2

Jessica Cusato, Lucio Boglione, Amedeo De Nicolò, Rosaria Imbornone et al. "Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients", Pharmacogenomics, 2017

Crossref

45 words — 1%

---
- 3

[hal-pasteur.archives-ouvertes.fr](http://hal-pasteur.archives-ouvertes.fr)

Internet

37 words — 1%

---
- 4

Ruochan Chen, Ju Zou, Liyuan Long, Haiyue Huang, Min Zhang, Xuegong Fan, Yan Huang. "Safety and Efficacy of Tenofovir Alafenamide Fumarate in Early-Middle Pregnancy for Mothers With Chronic Hepatitis B", Frontiers in Medicine

Internet

31 words — 1%

---
- 5

[coek.info](http://coek.info)

Internet

27 words — 1%

---
- 6

[www.library.umaine.edu](http://www.library.umaine.edu)

Internet

26 words — 1%

---



7	Henry Lik-Yuen Chan, Magdy Elkhatab, Huy Trinh, Won Young Tak et al. "Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B", Journal of Hepatology, 2015 Crossref	22 words — 1%
8	<a href="http://www.researchgate.net">www.researchgate.net</a> Internet	22 words — 1%
9	"UEG Week 2019 Poster Presentations", United European Gastroenterology Journal, 2019 Crossref	21 words — 1%
10	Oguz Karabay, Nazan Tuna, Şaban Esen. "Comparative efficacy of pegylated interferons α-2a and 2b in the treatment of HBeAg-negative chronic Hepatitis B infection", European Journal of Gastroenterology & Hepatology, 2012 Crossref	21 words — 1%
11	<a href="http://www.science.gov">www.science.gov</a> Internet	21 words — 1%
12	Quanxin Wu, Hongfei Huang, Xiaowen Sun, Meimin Pan et al. "Telbivudine Prevents Vertical Transmission of Hepatitis B Virus From Women With High Viral Loads: A Prospective Long-Term Study", Clinical Gastroenterology and Hepatology, 2015 Crossref	20 words — 1%
13	<a href="http://ajpendo.physiology.org">ajpendo.physiology.org</a> Internet	16 words — < 1%
14	<a href="http://bmcinfectdis.biomedcentral.com">bmcinfectdis.biomedcentral.com</a> Internet	15 words — < 1%
15	<a href="http://www.med.nagoya-u.ac.jp">www.med.nagoya-u.ac.jp</a> Internet	

15 words — < 1%

---

16 David Palmer, Steven Soule, Ravinder Reddy Gaddam, Peter Elder, Stephen Chambers, Matthew Doogue. "Unbound Vitamin D Concentrations Are Not Decreased in Critically Ill Patients", Internal Medicine Journal, 2020  
Crossref 14 words — < 1%

---

17 casopisi.junis.ni.ac.rs  
Internet 13 words — < 1%

---

18 Kai Yang, Ying Pan, Hao Zhang, Lei Jin, Xian Wang. "Hepatic vitamin D receptor expression is negatively associated with liver inflammation and fibrosis in patients with chronic HBV infection", Clinical and Experimental Medicine, 2022  
Crossref 12 words — < 1%

---

19 assets.researchsquare.com  
Internet 12 words — < 1%

---

20 www.slideshare.net  
Internet 12 words — < 1%

---

21 Chen, Huey-Ling, Chien-Nan Lee, Chin-Hao Chang, Yen-Hsuan Ni, Ming-Kwang Shyu, Shih-Ming Chen, Jen-Jan Hu, Hans Hsienhong Lin, Lu-Lu Zhao, Shu-Chi Mu, Ming-Wei Lai, Chyi-Long Lee, Hsien-Ming Lin, Ming-Song Tsai, Jenn-Jeih Hsu, Ding-Shinn Chen, K. Arnold Chan, and Mei-Hwei Chang. "Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus", Hepatology, 2015.  
Crossref 11 words — < 1%

- 
- 22 Jessica Cusato, Lucio Boglione, Amedeo De Nicolò, Chiara Simona Cardellino et al. "Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia", *Pharmacogenetics and Genomics*, 2016  
Crossref 11 words — < 1%
- 
- 23 Mohamed A Ahmed, Abdelmageed Elmugabil, Ashwaq AlEed, Abdullah Al-Nafeesah, Ishag Adam. "Maternal and neonatal umbilical cord serum levels of 25-hydroxy vitamin D among Sudanese women with normal pregnancy: a cross-sectional study", *Research Square Platform LLC*, 2023  
Crossref Posted Content 11 words — < 1%
- 
- 24 [brage.bibsys.no](https://brage.bibsys.no)  
Internet 11 words — < 1%
- 
- 25 [e-jnh.org](https://e-jnh.org)  
Internet 11 words — < 1%
- 
- 26 [www.ijidonline.com](https://www.ijidonline.com)  
Internet 11 words — < 1%
- 
- 27 [www.wjgnet.com](https://www.wjgnet.com)  
Internet 11 words — < 1%
- 
- 28 H Tsugeno. "Quantitative analysis of wild-type and precore mutant hepatitis B virus in carriers", *Hepatology Research*, 2002  
Crossref 10 words — < 1%
- 
- 29 [cslide.ctimeetingtech.com](https://cslide.ctimeetingtech.com)  
Internet 10 words — < 1%
- 
- 30 [vitamindwiki.com](https://vitamindwiki.com)  
Internet 10 words — < 1%

---

31

[www.atsjournals.org](http://www.atsjournals.org)  
Internet

10 words — < 1%

---

32

[www.medigraphic.com](http://www.medigraphic.com)  
Internet

10 words — < 1%

---

33

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)  
Internet

10 words — < 1%

---

---

EXCLUDE QUOTES	ON	EXCLUDE SOURCES	< 10 WORDS
EXCLUDE BIBLIOGRAPHY	ON	EXCLUDE MATCHES	< 10 WORDS